TPCB Faculty
David Scheinberg, MD, PhD
Memorial Sloan Kettering Cancer Center
Education
MD, 1983, The Johns Hopkins University School of Medicine
PhD, 1983, The Johns Hopkins University School of Medicine
AB, 1977, Cornell University
Research Topics
- Biotechnology
- Protein engineering
- Nanotechnology
- Radiochemistry
- Biological therapies
Therapeutic Areas
- Cancer
- Immunology
The overall goals of the Scheinberg lab are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes passive agents (antibodies, targeted nano-devices, and ligands) and active agents (vaccines). An important goal is to take these new therapies into human clinical trials for testing.
Read more about Prof. Scheinberg’s research on the Sloan Kettering website